[Cutaneous side effects of sorafenib and sunitinib].
Autier
J
J
Service de dermatologie, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.
Mateus
C
C
Wechsler
J
J
Spatz
A
A
Robert
C
C
D000169:Acrodermatitis / Q000139:chemically induced; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D006201:Hair Diseases / Q000139:chemically induced; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D009260:Nail Diseases / Q000139:chemically induced; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D012867:Skin / Q000187:drug effects; D000077157:Sorafenib; D000077210:Sunitinib; D048490:raf Kinases / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor; D048490:raf Kinases; D000077210:Sunitinib